MedTrace Logo

LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

NCT04479241 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-06-05

Study results available
· View outcomes & findings →

Summary

This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.

Conditions

Interventions

BIOLOGICAL

lerapolturev

Lerapolturev (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).

BIOLOGICAL

pembrolizumab

Pembrolizumab (200 mg IV) given every 3 weeks.

Sponsors & Collaborators

  • Istari Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Lisa Franklin · Istari Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-21
Primary Completion
2024-06-05
Completion
2024-06-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04479241 on ClinicalTrials.gov